Skip to main content

IDWeek 2024 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

Back

hongxia wei, n/a

The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, China

Disclosure(s): No financial relationships to disclose

Poster(s):

(P-587) Durable Virological Suppression, Reduced Body Weight, and Improved Serum Cholesterol after Switch to Tenofovir DF-Containing, Ainuovirine-Based Antiretroviral Regimen in People with HIV-1: the 96-Week Results of the SPRINT Trial, a Randomized, Active-Controlled Phase 3 Extensional Study

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT
(P-588) Improved Lipid Profile in Virologically Suppressed People with HIV-1 Switching to Tenofovir DF-Containing, Ainuovirine-Based Compared to Tenofovir Alafenamide-Containing, Boosted Elvitegravir-Based Antiretroviral Regimen: the Secondary Analyses of 48-Week Results of the SPRINT Trial, a Randomized, Active-Controlled Phase 3 Study

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT
(P-589) Cholesterol Control in Virologically Suppressed People with HIV-1 Switching to Tenofovir DF-containing, Ainuovirine-Based Compared to Tenofovir Alafenamide-Containing, Boosted Elvitegravir-Based Antiretroviral Regimen: Hypercholesterolemic Subgroup Analyses of the SPRINT Trial, a Randomized, Active-Controlled Phase 3 Study

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT